📊 BHIC Key Takeaways
Is BioScience Health Innovations, Inc. (BHIC) a Good Investment?
BHIC demonstrates exceptional profitability with 64.8% gross margins and 21.3% net margins, supported by explosive 208.7% YoY revenue growth. The company maintains a fortress balance sheet with zero debt, $1.1M cash, and strong returns on equity (51.2%) and assets (42.4%), though concerns exist around modest operating cash flow conversion and micro-cap scale.
BioScience Health Innovations shows sharp top-line acceleration, solid gross margins, and newly meaningful profitability, with a clean balance sheet and ample cash relative to liabilities. However, the business remains very small, cash conversion is much weaker than reported earnings, and several key liquidity details are missing, which makes the quality and durability of recent results less certain.
Why Buy BioScience Health Innovations, Inc. Stock? BHIC Key Strengths
- Exceptional gross margin of 64.8% indicates strong pricing power and operational efficiency
- Explosive 208.7% YoY revenue growth demonstrates significant market traction and scalability
- Outstanding profitability metrics with 21.3% net margin and 51.2% ROE
- Zero debt with positive stockholders' equity of $1.7M provides financial flexibility
- Massive interest coverage ratio of 1946x indicates no solvency risk
- Revenue growth of 208.7% YoY indicates strong recent operating momentum
- Profitability is solid with 64.8% gross margin and 21.3% operating and net margins
- Balance sheet appears conservative with $1.14M cash, low liabilities, and no meaningful long-term debt
BHIC Stock Risks: BioScience Health Innovations, Inc. Investment Risks
- Micro-cap company with only $4.1M revenue creates execution risk and limited track record at scale
- Operating cash flow of $272.9K significantly lags net income of $875.7K (31% conversion), raising quality of earnings concerns
- No insider buying activity in last 90 days could indicate limited management confidence
- Minimal current and quick ratio data unavailable, suggesting potential working capital management gaps
- Single period of strong growth requires validation of sustainability in subsequent reporting periods
- Operating cash flow of $272.87K trails net income of $875.72K, suggesting weaker earnings-to-cash conversion
- The company operates at very small scale, which can make results volatile and less resilient
- Missing liquidity and capital spending detail limits visibility into working capital quality and reinvestment needs
Key Metrics to Watch
- Revenue growth sustainability and YoY acceleration/deceleration trends
- Operating cash flow conversion ratio relative to net income for quality of earnings
- Gross margin maintenance as revenue scales
- Customer concentration and retention metrics
- Working capital efficiency and cash conversion cycle
- Operating cash flow relative to net income
- Revenue growth and operating margin consistency
BioScience Health Innovations, Inc. (BHIC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BHIC Profit Margin, ROE & Profitability Analysis
BHIC vs Technology Sector: How BioScience Health Innovations, Inc. Compares
How BioScience Health Innovations, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioScience Health Innovations, Inc. Stock Overvalued? BHIC Valuation Analysis 2026
Based on fundamental analysis, BioScience Health Innovations, Inc. appears fundamentally strong relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioScience Health Innovations, Inc. Balance Sheet: BHIC Debt, Cash & Liquidity
BHIC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioScience Health Innovations, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.01 reflects profitable operations.
BHIC Revenue Growth, EPS Growth & YoY Performance
BHIC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $573.0K | -$8.8K | $0.00 |
| Q2 2025 | $384.2K | $20.8K | $0.00 |
| Q1 2025 | $277.6K | -$53.4K | $0.00 |
| Q3 2024 | $192.2K | -$53.4K | $0.00 |
| Q2 2024 | $69.5K | $20.8K | N/A |
| Q1 2024 | $32.3K | -$53.4K | N/A |
| Q3 2023 | $19.7K | -$1.9K | N/A |
| Q2 2023 | N/A | -$1.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioScience Health Innovations, Inc. Dividends, Buybacks & Capital Allocation
BHIC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioScience Health Innovations, Inc. (CIK: 0001784440)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BHIC
What is the AI rating for BHIC?
BioScience Health Innovations, Inc. (BHIC) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BHIC's key strengths?
Claude: Exceptional gross margin of 64.8% indicates strong pricing power and operational efficiency. Explosive 208.7% YoY revenue growth demonstrates significant market traction and scalability. ChatGPT: Revenue growth of 208.7% YoY indicates strong recent operating momentum. Profitability is solid with 64.8% gross margin and 21.3% operating and net margins.
What are the risks of investing in BHIC?
Claude: Micro-cap company with only $4.1M revenue creates execution risk and limited track record at scale. Operating cash flow of $272.9K significantly lags net income of $875.7K (31% conversion), raising quality of earnings concerns. ChatGPT: Operating cash flow of $272.87K trails net income of $875.72K, suggesting weaker earnings-to-cash conversion. The company operates at very small scale, which can make results volatile and less resilient.
What is BHIC's revenue and growth?
BioScience Health Innovations, Inc. reported revenue of $4.1M.
Does BHIC pay dividends?
BioScience Health Innovations, Inc. does not currently pay dividends.
Where can I find BHIC SEC filings?
Official SEC filings for BioScience Health Innovations, Inc. (CIK: 0001784440) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BHIC's EPS?
BioScience Health Innovations, Inc. has a diluted EPS of $0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BHIC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BioScience Health Innovations, Inc. has a BUY rating with 70% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is BHIC stock overvalued or undervalued?
Valuation metrics for BHIC: ROE of 51.2% (sector avg: 22%), net margin of 21.3% (sector avg: 18%). Higher ROE suggests strong returns relative to peers.
Should I buy BHIC stock in 2026?
Our dual AI analysis gives BioScience Health Innovations, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is BHIC's free cash flow?
BioScience Health Innovations, Inc.'s operating cash flow is $272.9K, with capital expenditures of N/A. FCF margin is 6.6%.
How does BHIC compare to other Technology stocks?
Vs Technology sector averages: Net margin 21.3% (avg: 18%), ROE 51.2% (avg: 22%), current ratio N/A (avg: 2.5).
Why is BHIC's return on equity (ROE) so high?
BioScience Health Innovations, Inc. has a return on equity of 51.2%, significantly above the Technology sector average of 22%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 21.3% net margin.